Barclays analyst Peter Lawson lowered the firm’s price target on MacroGenics (MGNX) to $3 from $8 and keeps an Overweight rating on the shares post the earnings report. The firm de-risked the model to reflect the current market environment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX:
- MacroGenics reports Q1 EPS (65c), consensus (69c)
- MGNX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- MacroGenics price target lowered to $2 from $4 at H.C. Wainwright
- MacroGenics: Hold Rating Amidst Development Halts and Financial Challenges
- MacroGenics Inc’s 2024 Earnings Call Highlights